US EditionResmetirom for Nonalcoholic Fatty Liver Disease: a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial
- From May 2021 to April 2023, a global, placebo-controlled Phase III study involving 800 participants across 253 sites investigated the efficacy of semaglutide in treating metabolic dysfunction-associated steatohepatitis .
- The trial followed renaming of non-alcoholic fatty liver disease to MASLD and NASH to MASH in 2023, reflecting updated disease classifications.
- Eight hundred participants with MASH received semaglutide or placebo, with 62.9% of the semaglutide group showing reduced liver inflammation and fat compared to 34.3% on placebo.
- Semaglutide recipients lost 10.5% body weight and 36.8% experienced fibrosis improvement, though adverse events like diarrhea and nausea occured more often than in placebo patients.
- These results highlight semaglutide's potential to treat MASLD, a disease with no licensed medications, and support ongoing research into long-term liver outcomes.
35 Articles
35 Articles
Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial
Nonalcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. MAESTRO-NAFLD-1 was a 52-week randomized, double-blind, placebo-controlled phase 3 trial evaluating the safety of resmetirom in adults with nonalcoholic fatty liver disease and presumed NASH. Patients were randomized to three double-blind arms (100 mg resmetirom (n = 325), 80 mg resmetirom (n = 327) or placebo (n = 320)) or open-label 100 mg resmetirom…
New genetic factor identified in worsening of MASLD, with vitamin B3 as the most effective therapeutic agent
Approximately 30% of the global population is affected by metabolic-associated fatty liver disease (MASLD), a condition that previously lacked targeted treatments. Researchers have now identified a genetic factor that exacerbates the disease, and remarkably, the FDA-approved drug that most effectively targets this factor is vitamin B3.
Can Semaglutide Halt or Even Reverse Fatty Liver Disease? – Patient Worthy
The results released from the Phase III ESSENCE clinical trial, and recently published by Medical Xpress and in the NEJM, found that the drug semaglutide is effective in the treatment of fatty liver disease. Semaglutide is classified as a receptor agonist, a drug that binds to a specific receptor and activates a biological response. It […]
Coverage Details
Bias Distribution
- 87% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
